Bavarian Biotech Report 2011/2012 (7MB) - Bio M

Transcatheter Technologies GmbHBIOTECH DEVICES & REAGENTSKeywords: Devices, Cardiovascular DiseasesTRANSCATHETER TECHNOLOGIES develops medical devices aimed at reducingthe trauma of open-heart valve surgeries. Its re-positionable transcatheteraortic valve system TRINITY is at the forefront of next generation valveimplantation technology. The new technology makes it possible to implantaortic valve prostheses without the need for traumatic open-heart surgery.Key features of TRINITY allow the physician to reposition the valve duringimplantation. ZERO PRESSURE CRIMPING technology protects the fragilebiological leaflets when the stent is folded and expanded. This will increasethe safety and durability of the valve prosthesis and will allow for implantationin younger patients.Contact:Dr. Wolfgang GoetzJosef-Engert-Str. 13D-93051 RegensburgPhone: +49 (0) 170 63099-20Fax: +49 (0) 941 63099-897E-Mail:wolfgang.goetz@transcathetertechnologies.comInternet: www.transcatheter-technologies.comTRION Pharma GmbHBIOTECH THERAPEUTICS & DIAGNOSTICSKeywords: Immune Therapy, Antibody, Drug DevelopmentTRION Pharma GmbH is a privately held biopharmaceutical company thathas established a novel approach to cancer immunotherapy. The Company’sunique family of trifunctional therapeutic antibodies, called Triomab ® ,simultaneously activates multiple immune defense mechanisms againstcancer. Removab ® (catumaxomab), the most advanced candidate of theTriomab ® family, received EU market approval for the intraperitoneal treatmentof malignant ascites. Removab ® is not only the first drug indicated forthe treament of malignant ascites, but also the first approved bispecific,trifunctional antibody worldwide. TRION employs about 90 people in Munichfor development and cGMP-manufacturing of its antibody products.Contact:Brigitte StempferFrankfurter Ring 193aD-80807 MünchenPhone: +49 (0) 89 324266-0Fax: +49 (0) 89 324266-199E-Mail: mail@trionpharma.deInternet: www.trionpharma.deTRION Research GmbHBIOTECH DNA/PROTEIN ANALYTICSKeywords: Drug Development, Antibody Production Service, Immune TherapyTRION Research GmbH, founded in 1998, is a Biotech research company and astrategic partner of TRION Pharma GmbH focusing on the generation of novelTriomab ® antibody candidates and the support of non-clinical and clinicaldevelopment of Triomab ® antibodies. The company offers ImmunomonitoringService, special antibody conjugation support, additional analytical service intumor biology and further analytical support for reagent control to investigators,study sponsors and CROs. TRION Research is ISO 9001:2008 certified.The core competences of the company are:Immunomonitoring and logistical support for clinical and non-clinical studiesSupply of purified antibodies (labeled and unlabeled) Developmentof immunological assaysContact:Brigitte StempferAm Klopferspitz 19D-82152 MartinsriedPhone: +49 (0) 89 700766-0Fax: +49 (0) 89 700766-11E-Mail: mail@trionresearch.deInternet: www.trionresearch.com115